Evaluation of Topoisomerase IIa Expression in Pancreatic Ductal Adenocarcinoma: A Pilot Study Using Chromogenic in situ Hybridization and Immunohistochemistry on Tissue Microarrays
References (33)
- et al.
Optimum anthracycline-based chemotherapy for early breast cancer
Lancet Oncol
(2001) - et al.
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
Ann Oncol
(2005) - et al.
Rates of Topo IIa and HER2 gene amplification and expression in epithelial ovarian carcinoma
Gynecol Oncol
(2004) - et al.
Gene expression alterations in the non-neo-plastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma
Mod Pathol
(2005) - et al.
Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer
Pancre-atology
(2005) - et al.
Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways
Mod Pathol
(2005) - et al.
Ductal adenocarcinoma of the pancreas
- et al.
Chromosome aberrations in solid tumors
Nat Genet
(2003) - et al.
Karyotypic abnormalities in tumours of the pancreas
Br J Cancer
(1993) - et al.
Chromosome abnormalities in pancreatic adenocar-cinoma
Genes Chromosomes Cancer
(1994)
Biology of HER2 and its importance in breast cancer
Oncology
Comparative assays for the HER2/neu oncogene status in breast cancer
Arch Pathol Lab Med
Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma
Breast Cancer Res Treat
Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis
Cancer Res
Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q and losses of 18q, 9p and 15q in pancreatic cancer
Genes Chromosomes Cancer
Immunohistochemical detection of human telomerase reverse tran-scriptase (h-TERT), topoisomerase IIa expression and apoptosis in endometrial adenocarcinoma and atypical hyperplasia
Int J Gynecol Pathol
Cited by (17)
Identification of a novel catalytic inhibitor of topoisomerase II alpha that engages distinct mechanisms in p53<sup>wt</sup> or p53<sup>−/−</sup> cells to trigger G2/M arrest and senescence
2022, Cancer LettersCitation Excerpt :Topo II enzyme is unquestionably one of the most critical proteins required for the untangling of newly replicated chromosomes. Owing to its importance in regulating cell cycle events and the fact that overexpression in human cancers correlates with advanced disease grade/stage and poor overall survival [18–22], topo IIα is an attractive therapeutic target. Logically, there is heightened interest in the identification and development of novel and more selective topo IIα inhibitors with minimal off-target effects.
The basics of immunohistochemistry
2020, In Situ Molecular Pathology and Co-expression AnalysesThe basics of in situ hybridization
2020, In Situ Molecular Pathology and Co-expression AnalysesThe biochemical basis of in situ hybridization and immunohistochemistry
2020, In Situ Molecular Pathology and Co-expression AnalysesOpportunities for translation: Targeting DNA repair pathways in pancreatic cancer
2014, Biochimica et Biophysica Acta - Reviews on CancerCitation Excerpt :In comparison, etoposide is considered a specific topoisomerase II inhibitor, and is used in the treatment of a number of solid malignancies [123]. Two studies reported that the gene encoding topoisomerase II, TOP2A, is amplified in 60–90% of PDAC cases where it is frequently co-amplified with ERBB2 which is found on the same chromosome [133,134]. However, the theranostic value of this is uncertain, and clinical trials involving topoisomerase II poisons have focused on their combination with other cytotoxic agents [124,135–139] but have not been found to be more effective or less toxic compared with other chemotherapeutic treatment approaches for PDAC.
Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis
2009, Cancer LettersCitation Excerpt :Alterations of HER2 and TOP2A have been reported in gastric cancer, with some evidence suggesting that TOP2A amplification might be the more frequently occurring of the two, although reports are conflicting [4,27]. TOP2A alterations have also been reported in other gastrointestinal cancers, including pancreatic cancer [28]; however, data on TOP2A copy number alterations in CRC are surprisingly limited [9]. The association between topoisomerase IIα expression and both advancing tumor stage and poor differentiation suggest that the protein may play a role in CRC progression.
- 1
Capt. E. Tsiambas, MD 19B Symis Street, Ag Paraskevi GR-15341 Athens (Greece) Tel./Fax +30 210 729 7977